The quadrivalent vaccine described by the patient usually refers to the vaccine for the prevention of human papillomavirus HPV, which is divided into bivalent, quadrivalent and nine-valent. Due to the patient’s age, physical condition and other factors, the doctor will usually recommend a more suitable vaccine, so it is not always recommended or necessarily not recommended to get the quadrivalent vaccine. Different vaccines usually have the following characteristics: 1. Bivalent: for women aged 9-45 years to prevent cervical precancerous lesions and cervical cancer; 2. Quadrivalent: for women aged 9-45 years and men aged 9-26 years to prevent cancer, precancerous lesions, atypical lesions, genital warts, and infections due to HPV6, HPV11, HPV16, HPV18 and other types of infections; 3. HPV vaccine is generally 3 doses, with an interval of about 2 months between the 2 adjacent doses. The HPV vaccine is not only preventive for patients who are not infected with HPV, but also for those who have been infected with HPV in the past. 80%-90% of HPV infections in the genital tract clear up naturally, but there is a risk of reinfection and morbidity, and about 50% of patients can produce low levels of antibodies after reinfection. In addition, the HPV vaccine is also of preventive significance for patients who have received treatment for cervical cancer lesions, reducing the chances of reinfection and morbidity. It should be noted that patients who receive the quadrivalent vaccine may experience adverse reactions such as redness and swelling at the injection site, fever, dizziness, and nausea, but these are generally less frequent and are due to the fact that the quadrivalent vaccine is generally well tolerated by patients aged 9-45 years. Patients who receive the nine-valent vaccine, on the other hand, may be more likely to experience adverse reactions. Patients are advised to follow their doctor’s instructions for the appropriate vaccine and to inform their doctor if they have any adverse reactions.